ebselen
Sign in to saveEbselen (also called PZ 51, DR3305, and SPI-1005), is a synthetic organoselenium molecule under preliminary investigation as a drug candidate. It belongs to the class of compounds related to benzene and its derivatives. It is being developed by the Seattle biotechnology company, Sound Pharmaceuticals, Inc. It has also been reported to target tubulin, blocking its polymerization.
Article
5 sectionsContents
- Synthesis
- History
- Research
- References
- External links
Ebselen (also called PZ 51, DR3305, and SPI-1005), is a synthetic organoselenium molecule under preliminary investigation as a drug candidate. It belongs to the class of compounds related to benzene and its derivatives. It is being developed by the Seattle biotechnology company, Sound Pharmaceuticals, Inc. It has also been reported to target tubulin, blocking its polymerization.
Ebselen has been entered into clinical trials as a lead compound intended for the potential treatment of various diseases. Its most advanced clinical trial is a Phase III study in people with Meniere's disease, completed in July 2024.